Historical Valuation
Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8230.35 is considered Overvalued compared with the five-year average of -4.52. The fair price of Praxis Precision Medicines Inc (PRAX) is between 26.88 to 153.39 according to relative valuation methord. Compared to the current price of 294.38 USD , Praxis Precision Medicines Inc is Overvalued By 91.91%.
Relative Value
Fair Zone
26.88-153.39
Current Price：294.38
91.91%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Praxis Precision Medicines Inc (PRAX) has a current Price-to-Book (P/B) ratio of 17.65. Compared to its 3-year average P/B ratio of 3.26 , the current P/B ratio is approximately 440.77% higher. Relative to its 5-year average P/B ratio of 3.00, the current P/B ratio is about 488.35% higher. Praxis Precision Medicines Inc (PRAX) has a Forward Free Cash Flow (FCF) yield of approximately -3.20%. Compared to its 3-year average FCF yield of -60.31%, the current FCF yield is approximately -94.70% lower. Relative to its 5-year average FCF yield of -60.02% , the current FCF yield is about -94.67% lower.
P/B
Median3y
3.26
Median5y
3.00
FCF Yield
Median3y
-60.31
Median5y
-60.02
Competitors Valuation Multiple
AI Analysis for PRAX
The average P/S ratio for PRAX competitors is 1581.42, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX.O) exhibits a P/S ratio of 8230.35, which is 420.44% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PRAX
1Y
3Y
5Y
Market capitalization of PRAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PRAX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PRAX currently overvalued or undervalued?
Praxis Precision Medicines Inc (PRAX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8230.35 is considered Overvalued compared with the five-year average of -4.52. The fair price of Praxis Precision Medicines Inc (PRAX) is between 26.88 to 153.39 according to relative valuation methord. Compared to the current price of 294.38 USD , Praxis Precision Medicines Inc is Overvalued By 91.91% .
What is Praxis Precision Medicines Inc (PRAX) fair value?
PRAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Praxis Precision Medicines Inc (PRAX) is between 26.88 to 153.39 according to relative valuation methord.
How does PRAX's valuation metrics compare to the industry average?
The average P/S ratio for PRAX's competitors is 1581.42, providing a benchmark for relative valuation. Praxis Precision Medicines Inc Corp (PRAX) exhibits a P/S ratio of 8230.35, which is 420.44% above the industry average. Given its robust revenue growth of -100.00%, this premium appears unsustainable.
What is the current P/B ratio for Praxis Precision Medicines Inc (PRAX) as of Jan 09 2026?
As of Jan 09 2026, Praxis Precision Medicines Inc (PRAX) has a P/B ratio of 17.65. This indicates that the market values PRAX at 17.65 times its book value.
What is the current FCF Yield for Praxis Precision Medicines Inc (PRAX) as of Jan 09 2026?
As of Jan 09 2026, Praxis Precision Medicines Inc (PRAX) has a FCF Yield of -3.20%. This means that for every dollar of Praxis Precision Medicines Inc’s market capitalization, the company generates -3.20 cents in free cash flow.
What is the current Forward P/E ratio for Praxis Precision Medicines Inc (PRAX) as of Jan 09 2026?
As of Jan 09 2026, Praxis Precision Medicines Inc (PRAX) has a Forward P/E ratio of -21.34. This means the market is willing to pay $-21.34 for every dollar of Praxis Precision Medicines Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Praxis Precision Medicines Inc (PRAX) as of Jan 09 2026?
As of Jan 09 2026, Praxis Precision Medicines Inc (PRAX) has a Forward P/S ratio of 8230.35. This means the market is valuing PRAX at $8230.35 for every dollar of expected revenue over the next 12 months.